Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 6/20 | 0.40 |
| ▸ | DRD1 | P21728 | 6/20 | 0.40 |
| ▸ | DRD5 | P21918 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881712 | 0.78 | — | — | |
| SCHEMBL1525601 | 0.78 | — | — | |
| SCHEMBL22081972 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2A6DRD2DRD1DRD5 | |
| SCHEMBL109650 | 0.78 | CYP1A2 (0.62) | CYP1A2CYP2A6DRD2DRD1DRD5 | |
| Hydroxyamine SCHEMBL344671 | 0.76 | — | — | |
| SCHEMBL7913483 | 0.74 | CYP1A2 (0.59) | CYP1A2CYP2A6DRD2DRD1DRD5 | |
| Water SCHEMBL2528680 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL4314909 | 0.74 | — | — | |
| Bromide SCHEMBL2085597 | 0.74 | — | — | |
| Ammonia Solution, Strong SCHEMBL656057 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663463-B2 | 3-azabicyclo[3.1.0]hexane derivative and use thereof for medical purpose | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-29 | — | — | US | disclosed |
| EP-3072884-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2016-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280645-A1 | NOVEL 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSE | OPRM1, OPRD1, OPRK1 | CYP1A2 353/4885CYP2A6 273/4885DRD2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.